LCG Group

Teddington, United Kingdom

LCG Group

Teddington, United Kingdom
SEARCH FILTERS
Time filter
Source Type

News Article | July 13, 2017
Site: www.prweb.com

LGC Maine Standards announces that its VALIDATE® D-Dimer linearity and calibration verification test kit has received US FDA 510 (k) clearance for use on Siemens Sysmex® CS-2500 System analyzers. The VALIDATE® D-Dimer kit, in a human plasma matrix, evaluates D-Dimer. Each VALIDATE® D-Dimer kit, prepared using the CLSI EP06-A “equal delta” sample preparation, offers five distinct concentrations covering the reportable range for Siemens Sysmex® CS-2500 System analyzers. Each kit is liquid and ready-to-use. Simply dispense the product from each dropper bottle, directly into five sample cups, and run in replicates. Release of VALIDATE® D-Dimer for Siemens Sysmex® CS-2500 System analyzers allows clinical laboratories to complete their required D-Dimer linearity and calibration verification and maximize the reportable range while minimizing manual dilutions. Use of this product, while augmenting daily QC, assists with fulfilling various quality control requirements for linearity and calibration verification under CLIA, CAP, COLA, JCAHO, JCI and ISO 15189. The addition of VALIDATE® D-Dimer for Siemens Sysmex® CS-2500 System analyzers to the LGC Maine Standards expanding portfolio of products demonstrates a continued commitment to manufacture high-quality linearity and calibration verification products that meet industry needs. LGC Maine Standards is located in Cumberland Foreside, Maine and manufactures VALIDATE® linearity and calibration verification kits for over one hundred analytes, including General Chemistries, Urine Chemistries, Enzymes, Lipids, HbA1c, Therapeutic Drugs, Cardiac Markers, Thyroids, Serum Proteins, Vitamin D, Tumor Markers, Anemia, Fertility, Hemostasis and Whole Blood Glucose. LGC Maine Standards MSDRx® data reduction software is available at no charge for real-time data analysis or a laboratory can send their data to LGC Maine Standards where a technical specialist will complete the data analysis and return a report within five business days. About LGC LGC is an international life sciences measurement and testing company with leading positions in growing markets. LGC provides a range of measurement products and services which underpin the safety, health and security of the public, including reference materials and proficiency testing, calibration verification / linearity testing, genomics reagents and instrumentation, and expert sample analysis and interpretation. LGC serves customers across a number of end markets including Pharmaceuticals, Agricultural Biotechnology, Food, Environment, Government and Academia. LGC’s headquarters are in London and the company employs over 2,000 people, operating out of 22 countries worldwide. Its operations are extensively accredited to international quality standards such as ISO/IEC 17025, GMP, GLP, ISO Guide 34, ISO/IEC 17043 and ISO 13485:2003. With a history dating back to 1842, LGC has been home to the UK Government Chemist for more than 100 years and is the UK National Measurement Laboratory and Designated Institute for chemical and bio measurement. LGC was privatized in 1996 and is now owned by funds affiliated with KKR. For more information, please visit http://www.lgcgroup.com


News Article | July 11, 2017
Site: www.prweb.com

LGC Maine Standards confirms the immediate availability of VALIDATE® Linearity and Calibration Verification kits, which allow clinical laboratories to satisfy the requirements for calibration verification and analytical measurement range (AMR) verification as specified in the CAP Laboratory Accreditation Program (LAP) and current CLIA ‘88 Regulations, Section 493.1255. On July 06, 2017, the College of American Pathologists (CAP) informed customers that the June 19th shipments of the LN2-A and LN2VM-A LN program were delayed and a date for delivery had not yet been published. As noted in the announcement, laboratories that have not verified calibration within the last 6 months need to perform an alternative assessment for calibration verification and AMR verification. VALIDATE® kits, manufactured by LGC Maine Standards, satisfy these requirements and allow clinical laboratories to maintain compliance. VALIDATE® kits are liquid, ready-to-use and contain sufficient volume and open-vial stability to complete two testing cycles, plus troubleshooting, per instrument system. Therefore, a single order of VALIDATE® allows the clinical laboratory to recover from the CAP shipment delay and have material on- site for the December LN2-B and LN2VM-B test events. The General Chemistry (GC1, GC2, GC3, GC4), Lipoprotein (LP), Cardiac Markers (CM1) and Osmolality (OSMO) kits cover all of the analytes within the LN2-A and LN2VM-A offering. Each kit is prepared using the CLSI EP06-A “equal delta” sample preparation and offer five distinct concentrations. Simply dispense the product from each dropper bottle, directly into five sample cups, and run in replicates. VALIDATE® kits are available as instrument-specific configurations, tailor-made to specific analyzers, which maximize AMR coverage and minimize dilutions. Configurations are available for these and other automated chemistry systems: Abbott Laboratories, Beckman Coulter, Ortho Clinical Diagnostics, Roche Diagnostics and Siemens Healthineers. An order form is available at http://www.mainestandards.com/CAPdelay to afford laboratories a streamlined mechanism to access products for next-day shipments. LGC Maine Standards MSDRx® data reduction software is also available at no charge for real-time linearity data analysis. A laboratory can also send their data to LGC Maine Standards where a technical specialist will complete the data analysis and return a report with Peer Data Comparison, within five business days. Maine Standards remains committed to ensuring that high-quality linearity and calibration verification products are readily available to meet industry needs. About LGC LGC is an international life sciences measurement and testing company with leading positions in growing markets. LGC provides a range of measurement products and services which underpin the safety, health and security of the public, including reference materials and proficiency testing, calibration verification / linearity testing, genomics reagents and instrumentation, and expert sample analysis and interpretation. LGC serves customers across a number of end markets including Pharmaceuticals, Agricultural Biotechnology, Food, Environment, Government and Academia. LGC’s headquarters are in London and the company employs over 2,000 people, operating out of 22 countries worldwide. Its operations are extensively accredited to international quality standards such as ISO/IEC 17025, GMP, GLP, ISO Guide 34, ISO/IEC 17043 and ISO 13485:2003. With a history dating back to 1842, LGC has been home to the UK Government Chemist for more than 100 years and is the UK National Measurement Laboratory and Designated Institute for chemical and bio measurement. LGC was privatized in 1996 and is now owned by funds affiliated with KKR. For more information, please visit http://www.lgcgroup.com 1LGC Maine Standards is the brand name for Maine Standards Company, LLC.


News Article | June 5, 2017
Site: www.prweb.com

LGC Maine Standards announces the release of VALIDATE® IBC linearity and calibration verification kit. The VALIDATE® IBC kit, in a human serum matrix, evaluates Total Iron Binding Capacity (TIBC) and Unsaturated Iron Binding Capacity (UIBC). Each VALIDATE® IBC kit, prepared using the CLSI EP06-A “equal delta” sample preparation, offers five distinct concentrations covering the reportable range of most chemistry analyzers. Each kit is liquid and ready-to-use. Simply dispense the product from each dropper bottle, directly into five sample cups, and run in replicates. Release of VALIDATE® IBC allows clinical laboratories to complete their required TIBC and UIBC linearity and calibration verification and maximize the reportable range while minimizing manual dilutions. Use of this product, while augmenting daily QC, assists with fulfilling various quality control requirements for linearity and calibration verification under CLIA, CAP, COLA, JCAHO, JCI and ISO 15189. The addition of VALIDATE® IBC to the LGC Maine Standards expanding portfolio of products demonstrates a continued commitment to manufacture high-quality linearity and calibration verification products that meet industry needs. LGC Maine Standards is located in Cumberland Foreside, Maine and manufactures VALIDATE® linearity and calibration verification kits for over one hundred analytes, including General Chemistries, Urine Chemistries, Enzymes, Lipids, HbA1c, Therapeutic Drugs, Cardiac Markers, Thyroids, Serum Proteins, Vitamin D, Tumor Markers, Anemia, Fertility, Hemostasis and Whole Blood Glucose. LGC Maine Standards MSDRx® data reduction software is available at no charge for real-time data analysis or a laboratory can send their data to LGC Maine Standards where a technical specialist will complete the data analysis and return a report within five business days. About LGC LGC is an international life sciences measurement and testing company with leading positions in growing markets. LGC provides a range of measurement products and services which underpin the safety, health and security of the public, including reference materials and proficiency testing, calibration verification / linearity testing, genomics reagents and instrumentation, and expert sample analysis and interpretation. LGC serves customers across a number of end markets including Pharmaceuticals, Agricultural Biotechnology, Food, Environment, Government and Academia. LGC’s headquarters are in London and the company employs over 2,000 people, operating out of 22 countries worldwide. Its operations are extensively accredited to international quality standards such as ISO/IEC 17025, GMP, GLP, ISO Guide 34, ISO/IEC 17043 and ISO 13485:2003. With a history dating back to 1842, LGC has been home to the UK Government Chemist for more than 100 years and is the UK National Measurement Laboratory and Designated Institute for chemical and bio measurement. LGC was privatized in 1996 and is now owned by funds affiliated with KKR. For more information, please visit http://www.lgcgroup.com


News Article | August 15, 2017
Site: www.prnewswire.com

X1 offers the highest quality sports nutrition supplements for athletes of all ages. The X1 product line is All-Natural, Non-GMO, Gluten Free, Caffeine Free, and uses No Artificial Sweeteners or Flavors. X1 Founder, Brett Relander says, "We are honored to have the Informed-Choice and Informed-Sport stamp of approval as we continue to develop great tasting and nutritious all-natural products for student athletes and beyond." Relander went on to say, "Our customers trust is of the upmost importance to us and certifications like these show we're delivering on our promises." To celebrate their success and new certifications X1 is currently running a huge summer sale you don't want to miss. LGC has over 54 years of expertise in anti-doping and has published over 300 scientific papers on methods for detection of trace levels of substances that are prohibited in sport. The Informed-Choice and Informed-Sport programs are recognized globally through North America, Europe, South Africa, Australia, New Zealand and Japan. Testing includes over 200+ prohibited substances and products are tested against the various prohibited substance lists including WADA, NFL, MLB, NBA, NHL, MLS, PGA/WPGA, WTA, and NCAA. X1 Fuel is dedicated to helping athletes achieve their full potential, but they are more than just a sports nutrition company. They're a community of parents, coaches, athletes, nutritionists, trainers, and more. All with a mission to create positive leaders who not only make great nutritional choices, but also great life choices. The X1 Core Values are:


Grant
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: SC1-HCO-02-2016 | Award Amount: 2.08M | Year: 2017

Molecular in vitro diagnostics and biomedical research have allowed great progress in personalised medicine but further progress is limited by insufficient guidelines for pre-analytical workflow steps (sample collection, preservation, storage, transport, processing etc.) as well as by insufficient quality assurance of diagnostic practice. This allows using compromised patients samples with post collection changes in cellular and extra-cellular biomolecules profiles thus often making diagnostic test results unreliable or even impossible. To tackle this, SPIDA4P aims to generate and implement a comprehensive portfolio of 22 pan-European pre-analytical CEN/Technical Specifications and ISO/International Standards, addressing the important pre-analytical workflows applied to personalized medicine. These will also applicable to biomarker discovery, development and validation as well as to biobanks. Corresponding External Quality Assurance (EQA) Schemes will be developed and implemented as well, aiming to survey the resulting quality of samples and diagnostic practice. SPIDIA4P will ensure stakeholder organisations involvements as well as training, education, and counselling as additional major foci of the project. The consortium will closely coordinate with large European public research consortia to obtain access to research and validation studies data serving as evidence for the new standards developments and achieved improvements of diagnosis, patient stratification and prognosis of disease outcome. At this crucial moment in the development of personalised medicine, SPIDIA4P proposes a coordination and support action that reunites 19 highly experienced partners in international standardisation for in vitro diagnostics, coming from private industry including SMEs, public institutions and from one official European Standards Organisation. This strong consortium is balanced and empowered to maximise the impacts of in vitro diagnostics on personalised medicine.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-TP | Phase: KBBE.2012.2.2-01 | Award Amount: 7.65M | Year: 2012

The main objective of the BACCHUS project is to develop tools and resources that will facilitate the generation of robust and exploitable scientific evidence that can be used to support claims of a cause and effect relationship between consumption of bioactive peptides and polyphenols, and beneficial physiological effects related to cardiovascular health in humans. To achieve this, the BACCHUS consortium has assembled 12 leading Research & Technological centres and 16 SMEs (with ca 30% of the EC requested contribution allocated to the SMEs). BACCHUS thus contains SMEs directly involved in developing food products and pursuing health claims, experts in health claims legislation and the EFSA review process, and academic and industry partners who provide high quality food and health research that can underpin health claims. Existing SME-developed products that have clear potential for obtaining favourable opinions for health claims have been selected as test cases for study. These have been aligned with a series of work-packages each of which addresses key aspects of the EFSA health claim evaluation process (legislation and dossiers; product/bioactive characterisation; habitual intakes; bioavailability; mechanisms and biomarkers; clinical trials evidence of health benefit) that will deliver tools, processes and high quality original science. Scientific results and best practice guidelines will be made publically available and thus support future claims for industry. The scope and completeness of the existing bioactive database (eBASIS) that includes both compositional and biological effects data will be extended and developed as a sustainable tool with various training materials. All outcomes will be disseminated broadly by direct engagement with SMEs via an existing European SME association, with stakeholders via seminars, newsletters and press releases, as well as through traditional scientific routes (high quality publications, and conference presentations).


Grant
Agency: European Commission | Branch: FP7 | Program: MC-IAPP | Phase: FP7-PEOPLE-2012-IAPP | Award Amount: 871.61K | Year: 2013

Microbial communities are microorganisms (viruses, bacteria, fungi, algae) at the base of the food web pyramid, representing about 50 % of the total biomass on Earth. They are responsible for the biogeochemical cycles that shape the environment of earth and of its aquatic systems, influencing the health of each trophic and ultimately human health, too. In Europe, the good quality of surface waters is established under the Water Frame Directiv (WFD) based either on the chemical monitoring, or on the ecological status and pathogen detection in drinking and bathing waters. However, methods and techniques currently used for monitoring water quality and to detect potential biohazards present several limitations due to the need of highly skilled technicians; the long time for obtaining results, and the lack of tools for an integrated monitoring and evaluation of all different biological and non biological parameters relevant to guide preventive/remediation actions by the water authorities. MicroCokit, a close collaboration of academic groups with pan-European governmental laboratories and leading private enterprise, has been conceived to foster the transfer of knowledge among the partners with the final goal to bring to market faster, more sensitive and robust tools as bioindicators of water quality. The tools will be developed according to three different kind of bioindicators, 1) Microbial community bioindicator; ii) Pathogen indicator; iii) Early warning bioindicators for bacteria, cyanobacteria, and diatoms. The end-products will be of two kinds: a ready to use plate containing defined primers for quantitative Real Time PCR (qPCR) targeting the developed bioindicators and probes for Fluorescence in situ hybridization technique (FISH). The participation of two private enterprises already active in the field of molecular biology diagnostics, will facilitate the translation of this innovative ideas and tools into real products that will benefit European society.


Patent
LCG Group and University of Southampton | Date: 2014-06-18

There is provided a method of detecting the presence of a target polynucleotide and/or sequence variations within the target polynucleotide using a probe system comprising two independent partner oligonucleotide components wherein the first oligonucleotide has a first and second section, wherein the first section comprises a nucleotide sequence that is labelled with at least one visually detectable label and is not capable of hybridising to the nucleotide sequence of the target polynucleotide; and wherein the second section comprises a nucleotide sequence that is capable of hybridising to a portion of the sequence of the target polynucleotide; and the second oligonucleotide has a first and second section, wherein the first section comprises a nucleotide sequence which is capable of hybridising to a nucleotide sequence of the first section of the first oligonucleotide; and the second section comprises a nucleotide sequence that is capable of hybridising to a nucleotide sequence of the target polynucleotide that is adjacent to the nucleotide sequence that the second section of the first oligonucleotide is capable of hybridising to. There are also provided alternative methods using additional oligonucleotides and probes for use in such methods.


Patent
LCG Group | Date: 2012-06-18

In many situations, particularly in forensic science, there is a need to consider one piece of evidence against one or more other pieces of evidence. For instance, it may be desirable to compare a sample collected from a crime scene with a sample collected from a person, with a view to linking the two by comparing the characteristics of their DNA, particularly by expressing the strength or likelihood of the comparison made, a so called likelihood ratio. The method provides a more accurate or robust method for establishing likelihood ratios through the definitions of the likelihood ratios used and the manner in which the probability distribution functions for use in establishing likelihood ratios are obtained The methods provide due consideration of stutter and/or dropout of alleles in DNA analysis, as well as taking into consideration one or more peak imbalance effects, such as degradation, amplification efficiency, sampling effects and the like.


There is provided a single stranded oligonucleotide having a 5 end and a 3 end, said oligonucleotide comprising a first and second section, the first section being positioned 5 of the second section; and wherein (i) the first section is labelled with at least two detectable labels and is capable of hybridising to a target polynucleotide; and (ii) the second section is not capable of hybridising to a target polynucleotide; said second section comprising a stem-loop structure comprising a first portion, a second portion and a third portion and wherein the second portion is located between the first and third portions, and the first and third portions are complementary to each other. There is also provided a method of detecting the presence of a target polynucleotide and/or sequence variations within a target polynucleotide using such an oligonucleotide.

Loading LCG Group collaborators
Loading LCG Group collaborators